Skip to main content

Table 3 Factors associated with the risk of poor outcome (non-healing ulcers)

From: Poor prognostic factors in patients with newly diagnosed intestinal Adamantiades-Behçet’s disease in the Shanghai Adamantiades-Behçet’s disease database: a prospective cohort study

 

Univariate analysis

Multivariate analysis

OR (95% CI)

P

OR (95% CI)

P

Male sex

1.01 (0.61–1.70)

0.959

Age at the diagnosis of BS > 35 years

1.06 (0.63–1.77)

0.833

Onset of BS < 7 years

1.39 (0.85–2.27)

0.190

Intestinal symptoms

1.08 (0.64–1.82)

0.766

Endoscopic characteristics

  

Location (ileocecal and colorectum)

2.58 (1.63–4.07)

0.000

7.10 (1.81–27.86)

0.005

Number, ≥ 3

1.21 (0.72–2.04)

0.463

Size, > 1 cm

1.68 (1.02–2.76)

0.049

3.15 (0.91–10.84)

0.070

Lab parameters

WBC > 6.4, × 109/L

1.56 (0.92–2.66)

0.093

Hb < 123, g/L

1.81 (1.05–3.11)

0.026

ESR > 24, mm/h

2.85 (1.54–5.28)

0.000

5.97 (1.73–20.53)

0.005

CRP > 44, mg/L

1.94 (1.19–3.17)

0.014

Positive FOBT+

1.16 (0.64–2.09)

0.629

Positive T-SPOT

0.56 (0.22–1.39)

0.164

0.25 (0.05–1.35)

0.107

HBV-DNA

0.95 (0.30–3.05)

1.000

Treatment

Biologics

0.30 (0.17–0.54)

0.000

IFX therapy#

0.24 (0.12–0.50)

0.000

0.18 (0.04–0.85)

0.031

Poor compliance

3.95 (2.35–6.62)

0.000

8.56 (1.91–38.26)

0.005

  1. +FOBT: fecal occult blood test
  2. #IFX therapy was administrated at 0,2, and 6 weeks (intravenous), and then maintained with the same dosage of IFX every 8 weeks